Adherence to inhaled therapy, mortality and hospital admission in COPD. - Wikidata - wikimedia - TriplyDB

Adherence to inhaled therapy, mortality and hospital admission in COPD.

Adherence to inhaled therapy, mortality and hospital admission in COPD.

http://www.wikidata.org/entity/Q43286809

about

Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease Combined corticosteroid and long-acting beta 2 -agonist in one inhaler versus placebo for chronic obstructive pulmonary disease Inhaler technique: facts and fantasies. A view from the Aerosol Drug Management Improvement Team (ADMIT)Differential pharmacology and clinical utility of long-acting bronchodilators in COPD - focus on olodaterol Switching treatments in COPD: implications for costs and treatment adherence Optimizing management of chronic obstructive pulmonary disease in the upcoming decade.Defining and targeting health disparities in chronic obstructive pulmonary disease Getting less of what you want: reductions in statistical power and increased bias when categorizing medication adherence data.Severe COPD Exacerbation Risk and Long-Acting Bronchodilator Treatments: Comparison of Three Observational Data Analysis Methods."Show me the money": a fair criticism of economic studies on inhaled bronchodilators for COPD.Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis.Effect of pharmaceutical care on medication adherence and hospital admission in patients with chronic obstructive pulmonary disease (COPD): a randomized controlled study.Study protocol for a randomized, controlled trial comparing the efficacy of two educational interventions to improve inhalation techniques in patients with chronic obstructive pulmonary disease (COPD): TIEPOC Study.Treatment adherence and health outcomes in patients with bronchiectasis.The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD.A novel model-based approach for dose determination of glycopyrronium bromide in COPD AIMAR survey on complex forms of bronchial asthma and COPD, their management and perception of critical issues.Relationships between repeated instruction on inhalation therapy, medication adherence, and health status in chronic obstructive pulmonary disease.Enhancing the diagnosis and management of COPD in Primary care Low use and adherence to maintenance medication in chronic obstructive pulmonary disease in the general population.Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD.Impact of multiple-dose versus single-dose inhaler devices on COPD patients' persistence with long-acting β₂-agonists: a dispensing database analysis Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD Lower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease.Inhaled β-agonist does not modify sympathetic activity in patients with COPD.Improving outcomes in chronic obstructive pulmonary disease: the role of the interprofessional approach.Reducing hospital admissions and improving the diagnosis of COPD in Southampton City: methods and results of a 12-month service improvement project.Bronchodilators use in patients with COPD.Provider views about responsibility for medication adherence and content of physician-older patient discussions Survival in COPD: impact of lung dysfunction and comorbidities.Older patient, physician and pharmacist perspectives about community pharmacists' roles.COPD: it is time to change!Two-year mortality of patients with COPD in primary health care: an observational study Predictors of adherence to inhaled medications among Veterans with COPD.GFF MDI for the improvement of lung function in COPD - A look at the PINNACLE-1 and PINNACLE-2 data and beyond.Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk A review of the value of innovation in inhalers for COPD and asthma.Behavioral medicine approaches to chronic obstructive pulmonary disease.

P2860

Q24197853-F9F235DC-693F-429B-BCE5-BC32F3484FC9 Q24199130-B028D147-FF9E-4DA3-8CC4-0E1F1ED98D5F Q24202510-7E573D7A-FED2-46AB-ADBA-DC7683036F77 Q26751471-FEE6D6A2-3A97-4695-AA85-0E1107635BC6 Q26775244-86BE88F5-5AC2-4448-9EA9-6A1174E6930E Q26776324-3E26547C-6378-40DB-B3C0-5A9D8914049D Q27693341-8FF94607-B1E4-43BC-840E-768013C9D7E4 Q28073617-C14369EE-7C36-42F2-9186-ADF746949B47 Q31049583-5328C7DC-BA60-4520-B42F-77B36940F0C9 Q31137121-DF442521-D485-4A54-B80B-81B1AB451508 Q33693227-50B673BF-6EE8-4F6E-AF10-B3F0E850B595 Q33794408-EBE77B72-67E9-4374-8191-22CAABCCCEEB Q33814675-F12DFFFE-436A-43A2-B350-D9C786A7C8C3 Q33837011-249A0EA3-AB76-4A7F-A54C-B540D7A2B672 Q33877099-369A9C88-6324-4665-BE96-978B623629CD Q33966009-3A28A0FE-86C8-4E38-B08F-E27332E45748 Q34502782-62F44305-E708-401D-AC48-1E74C1980ED9 Q34514828-583F770F-5E80-40C1-944A-E0BA79B96E41 Q34621079-B86C84FA-8EA8-4949-86FE-22F0B6E8C580 Q34707897-1D6A6CF9-CC3B-4633-996A-B2E5189CACD1 Q34826231-B09FC875-B09B-4911-A75D-773537A2BF78 Q34962838-BD9D4AF0-B6C3-4760-B8B9-45651E256BB6 Q35061912-7718D4D1-3689-4FD9-B758-75DEB8E6356B Q35216376-8EF956C7-4EF3-4EBC-A91E-2E40987BFF98 Q35492192-68AFD3C9-27C8-4497-BC09-7FF1C2B63852 Q35617626-ABD46CA0-06CB-4CE0-901B-3A9746A7BB0E Q35618080-C0F60BB9-E2B6-4E5E-9C41-08198521C13E Q35821928-41EACD20-DAC2-4BEF-9A49-7164E3468313 Q35939406-27A3FD1B-CB67-4BCE-A456-4939ACD3340B Q36036881-BFDF95FC-F04D-475E-8207-13036B6CBF8F Q36053545-690A9B5C-58FF-42B8-85C4-C908A52EAF5D Q36193333-6D7CC265-D1E6-4275-B0AB-A9187C0491AA Q36235625-D9499A2B-9466-4A23-9FFC-A623DA037479 Q36288971-39D48DD2-3155-4A8A-BE50-0D0AD55DE2FF Q36308182-65DFF474-DAE6-4654-95C1-8F3896248757 Q36331378-A8D2434B-19F1-4EA3-AB04-E1BCEAEE1765 Q36356295-1FD0ABA4-39DD-4452-BD0B-51B264011E57 Q36412770-6D79C98D-15ED-46D1-A4A4-3D7F824564C4 Q36714639-2493883A-50C4-4F4F-BB72-B35FEEFB5059 Q36730719-8C7A5CD9-3CDE-4C05-A7F0-31522331B8AE

P2860

Adherence to inhaled therapy, mortality and hospital admission in COPD.

http://www.wikidata.org/entity/Q43286809

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Adherence to inhaled therapy, mortality and hospital admission in COPD.

@en

Adherence to inhaled therapy, mortality and hospital admission in COPD.

@nl

type

label

Adherence to inhaled therapy, mortality and hospital admission in COPD.

@en

Adherence to inhaled therapy, mortality and hospital admission in COPD.

@nl

prefLabel

Adherence to inhaled therapy, mortality and hospital admission in COPD.

@en

Adherence to inhaled therapy, mortality and hospital admission in COPD.

@nl

P1433

Q43286809-BF1EC704-F275-4BBE-AEF6-987CADB416E8

P1476

Q43286809-0969FEE1-175C-4639-8A30-EC68058308F1

P2093

Q43286809-4C00CD2F-7EA0-4ED2-8EB1-56D3EA7015BC

Q43286809-603EB3C2-292A-4993-81C1-8428141E4A1D

Q43286809-6262F377-F706-4DA5-A8AA-3136C87A9722

Q43286809-71DB213F-1290-49EF-829D-79E703EEA9E9

Q43286809-9743FE7B-BA8A-4B32-B842-656B22508F58

Q43286809-B8B4DCC0-9ED3-400D-98CE-F9C132A4B92D

Q43286809-E6943EAC-7029-4A63-B5CA-384168DDD942

Q43286809-EFC4E083-C1AF-4EF7-8C50-369CAF3EF823

Q43286809-F3FEEC5C-75C7-472D-8F37-08D6FF9DBD81

P304

Q43286809-90E5BB91-9B6C-43F1-A48C-4386D110D38E

P31

Q43286809-03241DB9-8CDA-4369-B365-C6C50994A68A

P356

Q43286809-E5CCBC5C-D4FD-4F96-874B-8905D9CA4048

P407

Q43286809-DE1FBD13-6367-4CCA-9D60-8CCE2DF57EC6

P433

Q43286809-EE1A7B55-B9E8-439D-9165-CEB3ED46E08D

P478

Q43286809-9D51F19C-348F-4EB4-A656-0825E5A919B2

P50

Q43286809-56E91990-8A77-463B-ADE7-C6572BB8C63C

P577

Q43286809-00A63396-78EB-417B-BFA6-3C0CA2CD57C0

P5875

Q43286809-BA70C9FB-26FC-4B61-BBB6-CB70925F4F53

P698

Q43286809-8D6CD08C-1596-4021-A24A-DDE7FAF20E32

P921

Q43286809-B17B7265-1DFA-4CAE-B19D-306A023F3165

P356

THX.2009.113662

P1433

P1476

Adherence to inhaled therapy, mortality and hospital admission in COPD.

@en

P2093

B Celli

http://www.w3.org/2001/XMLSchema#string

C Jenkins

http://www.w3.org/2001/XMLSchema#string

G T Ferguson

http://www.w3.org/2001/XMLSchema#string

J A Anderson

http://www.w3.org/2001/XMLSchema#string

J C Yates

http://www.w3.org/2001/XMLSchema#string

K Knobil

http://www.w3.org/2001/XMLSchema#string

L R Willits

http://www.w3.org/2001/XMLSchema#string

P M A Calverley

http://www.w3.org/2001/XMLSchema#string

P W Jones

http://www.w3.org/2001/XMLSchema#string

P304

939-943

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/THX.2009.113662

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26763993

http://www.w3.org/2001/XMLSchema#string

P698

19703830

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease